drugset / Trial / NCT01449578
Dexpramipexole SAD/MAD Study
RandomizedSingle-groupDouble-blindTreatment
Summary
This Phase 1 study will explore the safety, tolerability, and pharmacokinetics of single doses ranging from 300 to 600 mg and multiple daily doses ranging from 225 mg to 300 mg BID dexpramipexole in healthy volunteers.
Timeline
- Start
- 2011-11
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexpramipexole | Small molecule | 225 mg | Oral |
| Subject | Dexpramipexole | Small molecule | 300 mg | Oral |
| Subject | Dexpramipexole | Small molecule | 600 mg | Oral |